17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes.
性状
Solid
IC50 & Target[1][2]
CYP450 ω-hydroxylase
体内研究(In Vivo)
Infusion of 17-ODYA (16.5 nmol/min) directly into the renal cortical interstitium of rats produced a diuresis and a natriuresis which were associated with an increase in renal papillary blood flow in the absence of changes in renal blood flow, cortical blood flow or glomerular filtration rate.
17-ODYA (0.28 mg/kg; intracoronary; infusion for 2 to 3 minutes; dogs) markedly inhibits 20-HETE production during ischemia-reperfusion and produces a profound reduction in myocardial infarct size.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.